As Sage Therapeutics Inc. contemplates its path forward after rejecting a buyout offer from Biogen, its top executive ...
Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...
Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...
High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of ...
Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...
Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...
TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ETCompany ParticipantsChris Viehbacher - CEOConference ...
Clinical Trials Arena on MSN5d
Praxis Precision continues with ET trial despite likely failure warningUS-based Praxis Precision has decided not to halt its Phase III trial examining its essential tremor (ET) therapy after an ...
Sage Therapeutics (SAGE) announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the ...
Biogen Pharmachem Industries Ltd share price was down by -2.91% from the previous closing price of ₹1.03. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback